1330 - Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIS) Erlotinib and Gefitinib in the Treatment of Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

Abstract

ABSTRACT Background About 30–40% of all patients (pts) with NSCLC develop BM, leading to a poor prognosis and a median survival of Patients and methods Eligible pts had confirmed NSCLC and BM (≥1 lesion of ≥10mm diameter) aged >18 years with ECOG performanse status (PS) of 0–2. 15 pts received gefitinib (250mg/day) and 6 pts received erlotinib (150 mg/day) until radiologically-verified progressive disease. The primary endpoints were objective response rate (ORR) - complete and partial response in the brain and progressive-free survival (PFS) depending on presence of EGFR mutations. Secondary endpoint was the median of survival (MoS). From June 2007 to April 2012, 21 pts were enrolled in this study. Demographics were: median age: 54 years (range 46–80 years); male/female: 7/14; PS 1/2: 17/4; previously treated/untreated: 13/8; adenocarcinoma/squamous cancer: 19/2; number of BM ≤3/ > 3 14/7; non-smoker/smoker: 13/8, with EGFR mutations/without EGFR mutations – 12/9. Results Median PFS was 7 months overall, ORR was 75% (9/12, 8 partial responses, 1 complete response) and the MoS was not reached in patients with EGFR mutations. Median PFS was 2 months overall, no objective responses and the MoS was 4 months in patients without EGFR mutations. Differences are statistically significent in ORR and PFS (p Conclusions EGFR TKIs showed high effectiveness and good disease control in patients with brain metastases from NSCLC with EGFR mutations. Disclosure All authors have declared no conflicts of interest.